In the pathophysiology of psoriasis, tyrosine kinase 2 (TYK2) signaling pathways are connected; some TYK2 signaling pathways might be effective in treating psoriasis. In a study published in The New England Journal of Medicine, researchers aim to assess how selective TYK2 inhibition affects psoriasis.
In the phase 2, double-blind trial, the TYK2 inhibitor BMS-986165 was given to adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway. Patients (n=267) were randomly assigned to receive 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily, or to receive placebo.
— Rheumatology & Rheumatology Advances in Practice (@RheumJnl) September 12, 2018
— NEJM (@NEJM) September 12, 2018
The percentage of patients at week 12 with a 75% or greater reduction in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P=0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. https://t.co/uUseR0kuo3
— MelanomaResearchPapers (@MelanRes_papers) September 13, 2018
Results showed that “selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 weeks” but that more research needed to be completed to determine its safety and durability of effect in patients with psoriasis.
Check out an article on the relation of gout and hearing impairment in the elderly.